Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Other Investing Activities

Investing cash flows not reported separately.

Knight Therapeutics Inc.TSX: GUD.TO

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities turns positive

Q1 FY2026 other investing activities was CA$18.08M, compared with -CA$3.3M a year earlier. Trailing-twelve-month other investing activities was CA$11.17M.

Context

  • Other investing activities amounted to 3.9% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Other investing activities increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other investing activities holds near CA$18.08M or moves back toward the trailing-twelve-month quarterly average of CA$2.79M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$18.08M+13105.8% QoQ
Last fiscal yearDec 2025
CA$17.6M+224.6% YoY
LTMMar 2026
CA$11.17M+154.5% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+648.2%——
1 year+224.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

CAD · from the cash flow

Latest · FY2025
17.6M CAD
Year-over-year change
+224.6%
4-year CAGR
-47.0%

Other Investing Activities vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +154.5% is the 3rd highest of 8, against a peer median of +100.1%.
  • Other investing activities amounts to 2.2% of revenue for GUD.TO, versus a peer median of 1.7%.
GUD.TO Competitors
Other Investing Activities for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$49.82M CAD+5111.3%—15.6%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$11.17M CAD+154.5%—2.2%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$7.95M CAD-50.7%+28.8%12.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$6.74M CAD-83.9%-28.4%2.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$4.39M USD+253.7%-24.2%1.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$970K CAD-97.1%—0.4%
VHI.TOVitalhub Corp.LTM Mar 2026CA$931.76K CAD+144.8%—0.8%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$50K USD+100.1%—0.1%
Peer median (excluding GUD.TO) —+100.1%-24.2%1.7%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
Deferred Income Tax(7.64M)(17.13M)(9.13M)(3.24M)(3.81M)
Stock-Based Compensation3.05M1.89M2.33M1.86M8.11M
Change in Working Capital627K(9.99M)(28.01M)(19.62M)1.89M
Accounts Receivables8.59M(26.42M)5.58M(10.29M)(26.53M)
Inventory(17.19M)(11.43M)698K(5.91M)(17.82M)
Accounts Payables11.46M30.6M(21.63M)632K42.11M
Other Working Capital(2.23M)(2.74M)(12.66M)(4.06M)4.14M
Other Non-Cash Items(15.01M)32.98M37.19M(154K)12.91M
Operating Cash Flow44.62M40.48M35.94M36.28M70.3M
Capital Expenditures(224.18M)(25.82M)(9.96M)(31.47M)(1.91M)
Acquisitions (Net)(220.35M)000(110.05M)
Purchases of Investments(64.32M)(185.47M)(334.16M)(162.57M)(70.39M)
Sales of Investments180.54M150.54M345.47M196.12M112.43M
Other Investing Activities223.04M(2.33M)18.99M(14.12M)17.6M
Investing Cash Flow(105.28M)(63.08M)29.34M16.96M(84.11M)
Debt Repayment(14.19M)31.49M(18.02M)(18.05M)23.19M
Common Stock Issued0000511K
Common Stock Repurchased(64.42M)(30.07M)(53.48M)(8.87M)(6.35M)
Dividends Paid00000
Other Financing Activities297K(4.18M)(9.5M)(6.62M)(4.34M)
Financing Cash Flow(78.31M)1.76M(81M)(33.54M)13.01M
Effect of Forex Changes(4.66M)6.55M2.8M1.64M(2.86M)
Net Change in Cash(143.63M)(14.28M)(12.92M)21.35M(3.66M)
Free Cash Flow(179.57M)14.67M25.98M4.81M68.4M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.